Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

Bibliographic Details
Main Authors: Pinato, D, Brown, M, Trousil, S, Aboagye, E, Beaumont, J, Zhang, H, Coley, H, Mauri, F, Sharma, R
Format: Journal article
Language:English
Published: Springer Nature 2019
_version_ 1797078839184064512
author Pinato, D
Brown, M
Trousil, S
Aboagye, E
Beaumont, J
Zhang, H
Coley, H
Mauri, F
Sharma, R
author_facet Pinato, D
Brown, M
Trousil, S
Aboagye, E
Beaumont, J
Zhang, H
Coley, H
Mauri, F
Sharma, R
author_sort Pinato, D
collection OXFORD
description
first_indexed 2024-03-07T00:37:15Z
format Journal article
id oxford-uuid:81d9099c-1ac5-4342-b133-23d58e1a8056
institution University of Oxford
language English
last_indexed 2024-03-07T00:37:15Z
publishDate 2019
publisher Springer Nature
record_format dspace
spelling oxford-uuid:81d9099c-1ac5-4342-b133-23d58e1a80562022-03-26T21:33:04ZIntegrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinomaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:81d9099c-1ac5-4342-b133-23d58e1a8056EnglishSymplectic Elements at OxfordSpringer Nature2019Pinato, DBrown, MTrousil, SAboagye, EBeaumont, JZhang, HColey, HMauri, FSharma, R
spellingShingle Pinato, D
Brown, M
Trousil, S
Aboagye, E
Beaumont, J
Zhang, H
Coley, H
Mauri, F
Sharma, R
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
title Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
title_full Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
title_fullStr Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
title_full_unstemmed Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
title_short Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
title_sort integrated analysis of multiple receptor tyrosine kinases identifies axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
work_keys_str_mv AT pinatod integratedanalysisofmultiplereceptortyrosinekinasesidentifiesaxlasatherapeutictargetandmediatorofresistancetosorafenibinhepatocellularcarcinoma
AT brownm integratedanalysisofmultiplereceptortyrosinekinasesidentifiesaxlasatherapeutictargetandmediatorofresistancetosorafenibinhepatocellularcarcinoma
AT trousils integratedanalysisofmultiplereceptortyrosinekinasesidentifiesaxlasatherapeutictargetandmediatorofresistancetosorafenibinhepatocellularcarcinoma
AT aboagyee integratedanalysisofmultiplereceptortyrosinekinasesidentifiesaxlasatherapeutictargetandmediatorofresistancetosorafenibinhepatocellularcarcinoma
AT beaumontj integratedanalysisofmultiplereceptortyrosinekinasesidentifiesaxlasatherapeutictargetandmediatorofresistancetosorafenibinhepatocellularcarcinoma
AT zhangh integratedanalysisofmultiplereceptortyrosinekinasesidentifiesaxlasatherapeutictargetandmediatorofresistancetosorafenibinhepatocellularcarcinoma
AT coleyh integratedanalysisofmultiplereceptortyrosinekinasesidentifiesaxlasatherapeutictargetandmediatorofresistancetosorafenibinhepatocellularcarcinoma
AT maurif integratedanalysisofmultiplereceptortyrosinekinasesidentifiesaxlasatherapeutictargetandmediatorofresistancetosorafenibinhepatocellularcarcinoma
AT sharmar integratedanalysisofmultiplereceptortyrosinekinasesidentifiesaxlasatherapeutictargetandmediatorofresistancetosorafenibinhepatocellularcarcinoma